Literature DB >> 10467389

MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS).

F Barkhof1.   

Abstract

Magnetic resonance (MR) imaging is very sensitive in showing disseminated MS lesions. Subclinical MR progression occurs frequently, explaining why MR is now used to monitor treatment, even without measurable consequences, of new MR lesions to the patient at this moment. In the light of this clinico-radiological paradox, the significance of MR in MS is discussed, particularly in relation with the expanded disability status scale (EDSS). Gadolinium-enhancing lesions correlate with the occurrence of relapses, CSF myelin breakdown products and, in patients with relapsing-remitting disease, with higher EDSS. However, the predictive value of the frequency of enhancement for changes in EDSS is only weak. For conventional T2-weighted MR imaging, the cross-sectional correlation with EDSS varies between 0.15 and 0.60, and is limited mainly by the inherent lack of tissues specificity of T2-weighted images. Both T1 black holes and magnetisation transfer (MT) parameters show a better correlation with EDSS; it should be noted that lesions in which those abnormalities are found go through an initial phase of enhancement as well. For T1 black holes, a correlation up to 0.81 has been reported for SP patients. Post-mortem studies show that black holes and low MT ratios are in vivo markers of axonal loss. Preliminary data indicate that progressive atrophy also correlates with progression on the EDSS scale. More should be learned about the fate of new MR lesion with regards to development of axonal loss, which at present is difficult to predict in the enhancing stage. The existence of escape mechanisms, including remyelination, make a simple correlation with EDSS extremely unlikely, and perhaps not even desirable. Nevertheless, while the clinical effect of a given new lesion may be difficult to ascertain, the absence of (new) MR lesions is prognostically favourable, as will be the degree to which new lesions are prevented by treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10467389     DOI: 10.1177/135245859900500415

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  54 in total

1.  Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation.

Authors:  Jitendra Sharma; Michael P Sanfilipo; Ralph H B Benedict; Bianca Weinstock-Guttman; Frederick E Munschauer; Rohit Bakshi
Journal:  AJNR Am J Neuroradiol       Date:  2004 Jun-Jul       Impact factor: 3.825

Review 2.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

Review 3.  Neuroimaging in multiple sclerosis: neurotherapeutic implications.

Authors:  Nancy L Sicotte
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

4.  Whole-brain N-acetylaspartate concentration: correlation with T2-weighted lesion volume and expanded disability status scale score in cases of relapsing-remitting multiple sclerosis.

Authors:  Fabrice Bonneville; David M Moriarty; Belinda S Y Li; James S Babb; Robert I Grossman; Oded Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

5.  Can we overcome the 'clinico-radiological paradox' in multiple sclerosis?

Authors:  Kerstin Hackmack; Martin Weygandt; Jens Wuerfel; Caspar F Pfueller; Judith Bellmann-Strobl; Friedemann Paul; John-Dylan Haynes
Journal:  J Neurol       Date:  2012-03-24       Impact factor: 4.849

6.  Diffuse and focal corticospinal tract disease and its impact on patient disability in multiple sclerosis.

Authors:  Fernanda Tovar-Moll; Iordanis E Evangelou; Annie W Chiu; Sungyoung Auh; Christina Chen; Mary Ehrmantraut; Joan M Ohayon; Nancy Richert; Francesca Bagnato
Journal:  J Neuroimaging       Date:  2014-10-16       Impact factor: 2.486

7.  Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study.

Authors:  J M Stankiewicz; M Neema; D C Alsop; B C Healy; A Arora; G J Buckle; T Chitnis; C R G Guttmann; D Hackney; R Bakshi
Journal:  J Neurol Sci       Date:  2009-04-15       Impact factor: 3.181

8.  Relevance of the skewness index in DTI exploration of multiple sclerosis.

Authors:  Eliane Graulières; Jean-Albert Lotterie; Emmanuelle Cassol; Angélique Gerdelat; Michel Clanet; Isabelle Berry
Journal:  MAGMA       Date:  2008-11-08       Impact factor: 2.310

9.  Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis.

Authors:  James M Stankiewicz; Bonnie I Glanz; Brian C Healy; Ashish Arora; Mohit Neema; Ralph H B Benedict; Zachary D Guss; Shahamat Tauhid; Guy J Buckle; Maria K Houtchens; Samia J Khoury; Howard L Weiner; Charles R G Guttmann; Rohit Bakshi
Journal:  J Neuroimaging       Date:  2011-04       Impact factor: 2.486

10.  A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.

Authors:  C E Teunissen; A Petzold; J L Bennett; F S Berven; L Brundin; M Comabella; D Franciotta; J L Frederiksen; J O Fleming; R Furlan; R Q Hintzen; S G Hughes; M H Johnson; E Krasulova; J Kuhle; M C Magnone; C Rajda; K Rejdak; H K Schmidt; V van Pesch; E Waubant; C Wolf; G Giovannoni; B Hemmer; H Tumani; F Deisenhammer
Journal:  Neurology       Date:  2009-12-01       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.